Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 14 Results

Title
Intervention Indication Therapeutic Area Year Actions
Zolbetuximab for previously untreated advanced gastric or gastro-oesophageal junction adenocarcinoma Zolbetuximab (IMAB362) Gastro-oesophageal junction cancer Gastrointestinal Cancer 2022 View  |  Download
Trifluridine and Tipiracil for Metastatic Gastric Cancer – third line and above Lonsurf; TAS-102 (fixed dose combination: Trifluridine; Tipiracil hydrochloride) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2018 View  |  Download
Trastuzumab deruxtecan for HER2-positive gastric or gastroesophageal junction adenocarcinoma – third-line Trastuzumab deruxtecan (DS-8201a; Enhertu) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2021 View  |  Download
Rivoceranib for locally advanced or metastatic gastric or gastro-oesophageal junction cancer - after two or more therapies Rivoceranib (Apatinib; YN968D1) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2020 View  |  Download
Ramucirumab (Cyramza) + capecitabine or 5-FU + cisplatin for gastric cancer of GOJ – treatment naive for palliative chemotherapy 5-Fluorouracil , Capecitabine (Xeloda) , Cisplatin (Platinol) , Ramucirumab (Cyramza) Gastro-oesophageal junction cancer Gastrointestinal Cancer 2017 View  |  Download
Pembrolizumab plus chemotherapy for the treatment of gastric cancer or gastro-oesophageal junction cancer – First Line Pembrolizumab (Keytruda; MK-3475) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2021 View  |  Download
Pembrolizumab in addition to trastuzumab and chemotherapy for HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma – First-line Pembrolizumab (Keytruda; MK-3475) , Trastuzumab (Herceptin; RG-597) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2019 View  |  Download
Pembrolizumab in addition to chemotherapy for perioperative treatment of gastric or gastro-oesophageal junction adenocarcinoma FLOT , Pembrolizumab (Keytruda; MK-3475) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2019 View  |  Download
Pembrolizumab (KEYTRUDA) for advanced, metastatic oesophageal cancer – second line Pembrolizumab (Keytruda; MK-3475) Gastro-oesophageal junction cancer , Oesophageal cancer Gastrointestinal Cancer , Head and Neck Cancer 2017 View  |  Download
Pembrolizumab (Keytruda) for advanced gastric or gastroesophageal junction adenocarcinoma – first line Pembrolizumab (Keytruda; MK-3475) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2017 View  |  Download
1 2
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications